TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05016167

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Replacement every 24 hours
Description: Processing Steps:~1. The monitoring electrodes were not replaced for 24 hours, the electrodes were removed at the end of 24 hours. During the 24-hour follow-up, patients whose electrodes were removed for any reason were excluded from the sample.~2. Immediately after the drying, skin moisture measurement was made in the right 2nd intercostal space (ICA), left 2nd ICA, and midclavicular 5th ICA regions.~3. The skin condition was evaluated from the areas monitored using the skin condition score by the researcher and another independent observer.~4. The data were recorded.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Replacement every 12 hours
Description: Processing Steps:~1. Monitoring electrodes were removed at the end of the 12th hour. When removing the monitoring electrodes, the area was first wetted using a disinfectant and dried using a sponge after removing the electrodes.~2. Immediately after the drying, skin moisture measurement was made in the right 2nd ICA, left 2nd ICA and midclavicular 5th ICA regions.~3. The skin condition was evaluated from these areas monitored using the skin condition score by the researcher and another independent observer.~4. Monitored again.~5. Monitoring electrodes were removed at the end of the 24th hour. Cleaning and drying were done immediately after removal.~6. Immediately after drying, skin moisture was measured from the monitored areas.~7. The skin condition was evaluated from the areas monitored using the skin condition score by the researcher and another independent observer.~8. The data were recorded.
Study: NCT03220581

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Referral for care
Description: referral for addictions support
Study: NCT03745391

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MULTIMODAL COMPUTERIZED TOMOGRAPHY (Multimodal CT)
Description: After randomization, a MULTIMODAL CT will be performed to select treatment patient
Study: NCT01183572

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamins, Folic Acid, and Iron
Description: Daily oral dose containing 2500 IU Vitamin A, 1.4 mg Vitamin B1, 1.4 mg Vitamin B2, 2.6 mg Vitamin B12, 1.9 mg Vitamin B6, 18 mg Niacin, 70 mg Vitamin C, 14.9 IU Vitamin E, 30 mg elemental iron, 0.4 mg folic acid

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid and Iron
Description: Daily oral dose of 30 mg elemental iron, 0.4 mg folic acid

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Folic Acid
Description: Daily oral dose of 0.4 mg folic acid
Study: NCT03102424

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulator (DW1330)
Description: The 20 weeks of treatment of the DW1330 device, all the patients enrolled should perform 1 treatment within 1 hour after dinner 5 days a week.
Study: NCT03220581

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Referral for care
Description: referral for addictions support

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral therapy
Description: therapy focused on monitoring gaming behavior and replacing it with other activities and communication skills
Study: NCT03102424

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham DW1330 device
Description: The Sham DW1330 device will be masked by the same appearance as the study device (DW1330). The usage of time and location of Sham DW1330 device will be completely the same with study device (DW1330). However, the electronic model, including the frequency and time consistence of electronic stimulation are different between the Sham DW1330 device and the study device (DW1330). The 20 weeks of treatment of the DW1330 device, all the patients enrolled should perform 1 treatment within 1 hour after dinner 5 days a week.
Study: NCT03371394

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT04152330

Intervention type: OTHER
Group type: OTHER
Intervention: Early stimulation protocol on neuropsychomotor development of children with congenital heart disease
Description: A parenting guidance booklet will be prepared. It will contain a specific program of stimulation activities for each stage of development in simple language and with illustrations. Subdivided into 4 areas: Cognition, Language, Large Motor and Fine Motor. The duration will be 6 weeks. Parents will participate in 1 individual face-to-face meeting, where they will receive information and clarification on the application of the booklet and will have a mobile communication channel to answer questions throughout the process. Parents will be instructed on the capabilities and limitations of their babies according to the child's congenital heart disease, as well as what is expected within the typical development for this age group and the importance of early stimulation activities in each child in 4 areas of development.
Study: NCT03663374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odelepan
Description: Tablets, 125 mg
Study: NCT04282967

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: For the first 12 weeks on study (Part 1), participants will train with an exercise physiologist for 150 minutes/week. This training will be delivered by web-based video conferencing. For the next 12 weeks (Part 2), participants will be instructed to do patient-directed exercise.
Study: NCT01364662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPN-810
Description: administered orally
Study: NCT03663374

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Contains the same excipients as Odelepran but it does not contain the active agent. Placebo is identical to Odelepran in terms of drug form and external characteristics (colour, smell, etc). Doses and route of administration are identical to those for Odelepran.
Study: NCT03489967

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Induced-hypoglycemia test
Description: Participants will be admitted at the research center at 7:00 after an overnight fast. A venous catheter will be inserted into an arm vein for blood sampling purposes. A subcutaneous insulin bolus will be administered to induce hypoglycemia. Oral treatment (16g of carbohydrates or 32g of carbohydrates) will be given when plasma glucose levels are at the target threshold of \< 3.0 mmol/L or 3.0-3.5 mmol/L. Hypoglycemia symptoms will be assessed every 10 minutes by the participant using a validated scale starting from the time of insulin bolus until hypoglycemia recovery. One hour after hypoglycemia recovery, a standardized meal will be given.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Induced-hypoglycemia test
Description: Participants will be admitted at the research center at 7:00 after an overnight fast. A venous catheter will be inserted into an arm vein for blood sampling purposes. A subcutaneous insulin bolus will be administered to induce hypoglycemia. Oral treatment (16g of carbohydrates or 32g of carbohydrates) will be given when plasma glucose levels are at the target threshold of \< 3.0 mmol/L or 3.0-3.5 mmol/L. Hypoglycemia symptoms will be assessed every 10 minutes by the participant using a validated scale starting from the time of insulin bolus until hypoglycemia recovery. One hour after hypoglycemia recovery, a standardized meal will be given.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Induced-hypoglycemia test
Description: Participants will be admitted at the research center at 7:00 after an overnight fast. A venous catheter will be inserted into an arm vein for blood sampling purposes. A subcutaneous insulin bolus will be administered to induce hypoglycemia. Oral treatment (16g of carbohydrates or 32g of carbohydrates) will be given when plasma glucose levels are at the target threshold of \< 3.0 mmol/L or 3.0-3.5 mmol/L. Hypoglycemia symptoms will be assessed every 10 minutes by the participant using a validated scale starting from the time of insulin bolus until hypoglycemia recovery. One hour after hypoglycemia recovery, a standardized meal will be given.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Induced-hypoglycemia test
Description: Participants will be admitted at the research center at 7:00 after an overnight fast. A venous catheter will be inserted into an arm vein for blood sampling purposes. A subcutaneous insulin bolus will be administered to induce hypoglycemia. Oral treatment (16g of carbohydrates or 32g of carbohydrates) will be given when plasma glucose levels are at the target threshold of \< 3.0 mmol/L or 3.0-3.5 mmol/L. Hypoglycemia symptoms will be assessed every 10 minutes by the participant using a validated scale starting from the time of insulin bolus until hypoglycemia recovery. One hour after hypoglycemia recovery, a standardized meal will be given.
Study: NCT00016744

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium 4-Phenylbutyrate (4PBA)
Description: The standard oral adult dose is 20g/day (tablets) for 4 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unconjugated Isoflavones 100 (PTI G-4660, 87% Genistein)
Description: Every participant will be administered a perfusion of 50 MicroM of Genistein during the modified NPD procedure.
Study: NCT02153463

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Counselling
Description: Physical Activity Counselling weekly for 8 weeks
Study: NCT00408785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: botulinum toxin type A 100 units, human serum albumin 0.5 mg, sodium chloride 0.9 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium chloride
Description: sodium chloride 0.9 mg
Study: NCT00657748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Gluconate (drug) Glyceryl Triacetate GTA (drug)
Description: Lithium 1.3 mEq/kg/day (three administrations a day)during the study GTA 500 mg/kg/day in four administrations a day during the study
Study: NCT02003586

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: plant-based ingredient

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: plant-based ingredient

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: No plant-based ingredient

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: No plant-based ingredient
Study: NCT04177186

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training
Description: Strength training for hamstring and gastrocnemius only, pre and post 12 weeks of intervention

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Strength training with botulinum toxin
Description: Strength training for hamstring and gastrocnemius with Ultra Sound Imaging method, pre and post 12 weeks of intervention
Study: NCT02495584

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortified milk (10µg vitamin D3)
Study: NCT04423887

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lower Extremity Resistance Exercise Training
Description: Treadmill walking 5-10 min for warm up Strength training: (80% of 8RM)~3 times supervised exercise for 4 weeks Warm up (Self Paced walking for 10 minutes) leg press, leg extension, Sit to stand squat (mini squats) Stationary Cycling (Maximum Resistance as per patient tolerance till failure)~3 sets 8 reps 10-15 s rep rest interval 1-2 min set rest interval

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower Extremity Resistance Exercise Training
Description: Treadmill walking 5-10 min for warm up Strength training: (80% of 8RM)~3 times supervised exercise for 4 weeks Warm up (Self Paced walking for 10 minutes) leg press, leg extension, Sit to stand squat (mini squats) Stationary Cycling (Maximum Resistance as per patient tolerance till failure)~3 sets 8 reps 10-15 s rep rest interval 1-2 min set rest interval
Study: NCT02495584

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortified milk (10µg vitamin D3)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Unfortified milk (placebo)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Unfortified milk (placebo)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 10µg vitamin D3 supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 10µg vitamin D3 supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Study: NCT03677440

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treadmill Walking Exercise Training
Description: 12-weeks of supervised, progressive treadmill walking exercise training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching-and-Toning Exercise Training
Description: 12-weeks of supervised, progressive stretching-and-toning exercise training
Study: NCT00847249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9164
Description: Each subject will receive a single-dose starting dose 4µg (lung deposited dose) with up to 8 dose escalations not exceeding AstraZeneca pre-defined exposure limits.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each subject will receive a single-dose.
Study: NCT05646160

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ischemic Compression of Myofascial Trigger Points (IC-MTRPs)
Description: IC-MTrPs intervention was made first on the right side and then on the left side and this order was the same in each patient. Before starting the therapeutic procedure, the MTrPs localizations were identified by palpation and pinch pressure in patients lying back on the couch. During the procedure, a qualified physiotherapist sat behind the subject's head. The pressure was sustained for about 5 seconds with a 2-3 seconds pause. In each subject, the intervention lasted 15 minutes on the same measurement day in the morning. The subjects underwent cycle of seven IC-MTrPs therapeutic sessions, with 3 days brakes between each session, that lasted in total about a 3-weeks (25 days).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ischemic Compression of Myofascial Trigger Points (IC-MTRPs)
Description: IC-MTrPs intervention was made first on the right side and then on the left side and this order was the same in each patient. Before starting the therapeutic procedure, the MTrPs localizations were identified by palpation and pinch pressure in patients lying back on the couch. During the procedure, a qualified physiotherapist sat behind the subject's head. The pressure was sustained for about 5 seconds with a 2-3 seconds pause. In each subject, the intervention lasted 15 minutes on the same measurement day in the morning. The subjects underwent cycle of seven IC-MTrPs therapeutic sessions, with 3 days brakes between each session, that lasted in total about a 3-weeks (25 days).
Study: NCT00016744

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Unconjugated Isoflavones 100 (PTI G-4660, 87% Genistein)
Description: Every participant will be administered a perfusion of 50 MicroM of Genistein during the modified NPD procedure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo dose will match the oral tablets in arm 1, maintaining the study blind.
Study: NCT01068782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL184
Description: given orally as capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL184
Description: given orally as capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL184
Description: given orally as capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL184
Description: given orally as capsules
Study: NCT03855813

Intervention type: OTHER
Group type: OTHER
Intervention: Intra rater reliability
Description: Patients will perform the 30 seconds chair stand test as a self-test twice at home with approximately two days apart. The last self-test should be performed approximately one week before the testing with a physical therapist.

Intervention type: OTHER
Group type: OTHER
Intervention: Inter rater reliability
Description: Same patients performing the self-test will be tested by a physical therapist approximately one week after the last self-test. The physical therapist will be blind to the self-test results.
Study: NCT02529748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Participants for Surface Skin Sampling
Description: Skin wipe samples will be collected to quantify the amount of the test substances transferred to and from the surface of the participants' skin.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elemental metallic lead
Description: Consumer product fishing tackle made of elemental lead will be handled by the participants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tinopal
Description: Tinopal, a fluorescent tracer, will be handled by the participants.
Study: NCT03958656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300 mg/m\^2 intravenous (IV) over 30 minutes on days -5, -4, and -3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300 mg/m\^2 intravenous (IV) over 30 minutes on days -5, -4, and -3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2 intravenous (IV) over 30 minutes immediately following the cyclophosphamide on day -5, -4, and -3
Study: NCT01364662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: administered orally
Study: NCT01879241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasagiline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a sugar pill manufactured to mimic Rasagiline 1 mg tablet
Study: NCT03630575

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical cord blood and hair collection
Description: At the birth of the newborn, a first hair sample and a cord blood sample will be taken. A follow-up of the newborn will be performed between 4 and 6 months in order to obtain a second hair sample.
Study: NCT01375907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotavin
Description: Rotavin-M1, 10e6.3FFU/dose, 2 doses, 1-month between doses
Study: NCT04417881

Intervention type: OTHER
Intervention: MEESSI score
Description: MEESSI score in predicting mortality and readmission of patients managed for acute heart failure (AHF) in Emergency Department.
Study: NCT00598247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Poliglumex
Description: Paclitaxel Poliglumex 175 mg/m2 will be given over ten minutes every 3 weeks.
Study: NCT02074631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamidronate
Description: Subjects randomized to pamidronate treatment will receive infusions, 1 mg/kg (to a max dose of 60mg) over 4 hours, every 3 months at approximately 100 days, 180 days, and 270 days after HCT.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium and vitamin D
Description: All subjects will receive a standard recommended dose of 600 IU/day of vitamin D. Subjects who do not meet the RDA will receive additional calcium supplementation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D
Description: All subjects will receive a standard recommended dose of 600 IU/day of vitamin D. Subjects who do not meet the RDA will receive additional calcium supplementation.
Study: NCT03958656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2 intravenous (IV) over 30 minutes immediately following the cyclophosphamide on day -5, -4, and -3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimiducid
Description: 0.4 mg/kg of Rimiducid intravenous (IV) over 2 hours. (A maximum of 2 doses separated by at least 48 hours) Note: Rimiducid may be administered as needed based on the patient condition at the discretion of the Principal Investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimiducid
Description: 0.4 mg/kg of Rimiducid intravenous (IV) over 2 hours. (A maximum of 2 doses separated by at least 48 hours) Note: Rimiducid may be administered as needed based on the patient condition at the discretion of the Principal Investigator.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Signaling lymphocytic activation molecule F7 (SLAMF7) chimeric antigen receptor (CAR) T cells
Description: 0.3x10\^6- 12.0x10\^6 CAR+ T cells per kg of recipient bodyweight one-time dose on day 0
Study: NCT02155140

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Jejunal feeding
Description: A feeding jejunostomy tube is inserted at the time of surgery to provide enteral nutritional support.
Study: NCT00913042

Intervention type: OTHER
Intervention: sample blood
Description: * Early culture~* Bacterial DNA tests in blood
Study: NCT04415255

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EABPI plus IABPI
Description: If the patient was assigned to EPABI plus IABPI, while the extrapleural space was reached, \~ 15 ml of autologous blood was injected at the extrapleural space through the coaxial needle. Then the central stylet was reinserted and the coaxial needle was advanced into the lung parenchyma with a single puncture. The needle was stopped inside the proximal part of the target and the center needle was removed. A 20-G/16 cm fully-automated biopsy needle was introduced through the 19-G/13.8 cm coaxial needle and specimens were identically obtained. After specimens were collected, the biopsy needle was removed, and immediately the remaining autologous blood (\~5 ml) was slowly injected through the coaxial needle as it was withdrawn through the parenchyma thus sealing the needle tract.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IABPI-alone
Description: If the patient was assigned to IABPI-alone, after collecting the biopsy specimens, immediately the autologous blood (\~5 ml) was slowly injected through the coaxial needle as it was withdrawn through the parenchyma thus sealing the needle tract.
Study: NCT03512509

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low glycaemic potato
Description: The Carisma potato variety is used as the low glycaemic index potato.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High glycaemic potato
Description: The Arizona potato variety is used as the high glycaemic index potato.
Study: NCT02769247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Oral naproxen vs placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Oral naproxen vs placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Intrauterine lidocaine vs normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Intrauterine lidocaine vs normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: either normal saline or empty oral capsule